Study identification

PURI

https://redirect.ema.europa.eu/resource/46014

EU PAS number

EUPAS24207

Study ID

46014

Official title and acronym

Psoriasis Study of Health Outcomes – an International Observational Study of 3 Year Health Outcomes in the Biologic Treatment of Moderate to Severe Plaque Psoriasis (PSoHO)

DARWIN EU® study

No

Study countries

Argentina
Australia
Austria
Brazil
Canada
Colombia
France
Germany
Hungary
Israel
Italy
Korea, Republic of
Mexico
Netherlands
Poland
Portugal
Romania
Saudi Arabia
Spain
Switzerland
Taiwan
United Arab Emirates
United Kingdom

Study description

In order to evaluate the additional benefit of improved skin clearance for patients with psoriasis and the associated long term outcomes including patient reported HRQoL and health care resource consumption, the currently proposed study will explore the clinical effectiveness of anti IL 17A treatments (specifically ixekizumab and secukinumab) in patients with moderate to severe psoriasis compared to other biologic treatments within routine care.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Catherine Reed

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable